Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer Therapy

Considerable breakthroughs in the treatment of malignant tumors using antibody drugs, especially immunomodulating monoclonal antibodies (mAbs), have been made in the past decade. Despite technological advancements in antibody design and manufacture, multiple challenges face antibody‐mediated cancer...

Full description

Saved in:
Bibliographic Details
Published in:Advanced healthcare materials 2021-06, Vol.10 (11), p.e2002139-n/a
Main Authors: Ye, Qian‐Ni, Wang, Yue, Shen, Song, Xu, Cong‐Fei, Wang, Jun
Format: Article
Language:English
Subjects:
Antibodies
antibody drugs
Anticancer properties
Antitumor activity
Biocompatibility
Biomaterials
Biomedical materials
Cancer
cancer immunotherapy
Cancer therapies
cancer treatment
Cytotoxicity
delivery system
Drugs
Immobilization
Monoclonal antibodies
Therapy
Toxicity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Considerable breakthroughs in the treatment of malignant tumors using antibody drugs, especially immunomodulating monoclonal antibodies (mAbs), have been made in the past decade. Despite technological advancements in antibody design and manufacture, multiple challenges face antibody‐mediated cancer therapy, such as instability in vivo, poor tumor penetration, limited response rate, and undesirable off‐target cytotoxicity. In recent years, an increasing number of biomaterials‐based delivery systems have been reported to enhance the antitumor efficacy of antibody drugs. This review summarizes the advances and breakthroughs in integrating biomaterials with therapeutic antibodies for enhanced cancer therapy. A brief introduction to the principal mechanism of antibody‐based cancer therapy is first established, and then various antibody immobilization strategies are provided. Finally, the current state‐of‐the‐art in biomaterials‐based antibody delivery systems and their applications in cancer treatment are summarized, highlighting how the delivery systems augment the therapeutic efficacy of antibody drugs. The outlook and perspective on biomaterials‐based delivery of antitumor antibodies are also discussed. This review summarizes the current state‐of‐the‐art biomaterials‐based antibody delivery systems and their applications in cancer treatment from two main aspects: local delivery and systemic delivery, highlighting how the delivery systems can augment the therapeutic efficacy of antibody drugs. Even so, the translation of biomaterials‐based antibody delivery systems from lab to clinical application still requires further research and consideration.
ISSN:2192-2640
2192-2659
DOI:10.1002/adhm.202002139